Patients who forego sentinel lymph node biopsy after 31-GEP testing are not harmed: A prospective, multicenter analysis
Saved in:
| Main Authors: | J.M. Guenther, A. Ward, B. Martin, T. Beard, R. Sharma, S.P. Leong, M. Yamamoto, R. Cook |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824001630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma
by: J. Michael Guenther, et al.
Published: (2025-01-01) -
Identification of patients at high risk for relapse by Merlin Assay (CP-GEP) in an independent cohort of patients with melanoma who did not undergo sentinel lymph node biopsy: head and neck subgroup analysis
by: T. Amaral, et al.
Published: (2024-01-01) -
Sentinel Lymph Node Biopsy in Nonmelanoma Skin Cancer Patients
by: Marie-Laure Matthey-Giè, et al.
Published: (2013-01-01) -
Role of Sentinel Lymph Node Biopsy in the Management of Merkel Cell Carcinoma
by: Eric P. Arruda, et al.
Published: (2012-01-01) -
Indocyanine Green Fluorescence Plus Blue Dye for Sentinel Lymph Node Biopsy in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter, Prospective Cohort Study
by: Miao Liu, et al.
Published: (2025-01-01)